-
- ADME/DMPK for Stroke DrugsDrug Efficacy Testing for Stroke
- Cerebral Infarct Size Measurement
- Histological Assessment
- Physiological Monitoring
- Behavioral TestingBrain Imaging
- Cerebral Blood Flow Monitoring
- Brain Edema Measurement
- Assessment of Blood-Brain Barrier
- Assessment of Leukocyte-Platelet Aggregates
- Quantitative Analysis of Protein and mRNA Expression
Safety Assessment for Stroke DrugsIn Vitro Pharmacology for Stroke Drugs- Cell Viability Assay
- Caspase-3 Activity Assay
- In Vitro Neuroinflammatory Models and Assays
- Excitotoxicity In Vitro Assay
- Cell-Based Mitochondrial Function Assay
- In Vitro Oxidative Stress Assay
- Analysis of Ischemia-Triggered Glutamate Excitotoxicity
- NMDA Receptor-mediated Excitotoxicity
- AMPA Receptor-mediated Excitotoxicity
Molecular Mechanism Analysis of Oxidative Stress in StrokeAnalysis of Neuroinflammatory Mechanisms in Stroke- Molecular Mechanism Analysis of Ischemia-Reperfusion Injury
Cell Death Mechanism Analysis in Stroke- Autophagy Mechanism Analysis in StrokeApoptotic Mechanism Analysis after Cerebral Ischemia
- Ferroptosis Pathways
- Necroptosis Signaling Pathways
Epigenetic Mechanism Analysis in Stroke- Analysis of Gut Microbiota in Stroke
- Animal Modeling of Stroke
- Animal Modeling of Ischemic StrokeAnimal Modeling of Hemorrhagic StrokeIn Vitro Modeling of Stroke
- In Vitro Modeling of Ischemic Stroke
- In Vitro Modeling of Hemorrhagic Stroke
- Small-Molecule Antiplatelet DrugsNeuroprotective PeptidesMonoclonal Antibodies for StrokeStem Cell-Based Therapies for StrokeDrug Delivery SystemsInquiry
Stroke-Related Protein Biomarker Development Services
The variation in stroke outcomes among individuals is substantial, and studying proteins can help uncover the biological mechanismsbehind this variability. By employing various proteomic techniques, researchers have identified numerous proteins and proteomes that could serve as biomarkers for stroke. Conducting an exploratory analysis to discover proteins linked to stroke severity or outcomes may expedite the investigation of potential candidate molecules. However, given the vast array of possible targets and the intricate nature of biological systems, pinpointing significant protein biomarkers for focused analysis can be quite challenging.
Our Services
Ace Therapeutics' bioanalytical team has extensive experience in biomarker development, characterization and validation. We provide comprehensive protein biomarker development services to help clients study the pathophysiology, diagnosis, and prognosis of stroke. We are able to help discover stroke-related protein biomarkers, measure and interpret their changes in assay systems, and link them to drug development programs. Our protein biomarker development services deliver accurate and reliable results.
Types of Stroke-Related Protein Biomarkers We Can Develop
Our scientists use advanced proteomics techniques (e.g., mass spectrometry, array-based methods) to develop and validate a broad range of protein biomarkers for pharmaceutical and biotech companies focused on stroke.
Type of Proteins Examples Proteins involved in ischemic brain injury S100 calcium binding protein B (S-100B), neuron-specific enolase (NSE), myelin basic protein (MBP), glial fibrillary acidic protein (GFAP) Proteins involved in inflammation and immune response C-reactive protein (CRP), interleukin 6 (IL-6), tissue necrosis factor-alpha (TNF-alpha), vascular cell adhesion protein 1 (VCAM 1), intercellular adhesion molecule 1 (ICAM 1), N-methyl-d-aspartic acid (NMDA) receptor, matrix metalloproteinase (MMP) Proteins involved in acute thrombosis Fibrinogen, D-dimer, vascular hemophilic factor (vWF) Other proteins associated with stroke PARK7, nucleotide diphosphate kinase A (NDKA), B-type neurotrophic growth factor (BDNF) How to Develop Stroke-Related Protein Biomarkers
Discovery of Protein Biomarkers
- We use various technologies to perform proteomic analysis of samples such as blood, brain tissue, and cerebrospinal fluid, to screen for thousands of proteins that may be associated with stroke.
- We assist clients in the screening of the most promising protein biomarkers as candidates.
Validation of Protein Biomarkers
- We use orthogonal techniques such as immunoassays to validate the levels and reproducibility of these protein biomarkers in larger samples.
- We analyze the correlation of these protein biomarkers with indicators such as stroke incidence, severity, and prognosis to determine their biological significance.
Ace Therapeutics has a wide range of capabilities to support the identification and analysis of protein biomarkers for stroke. We have extensive experience in biomarker evaluation, including assay development and validation. Leverage our expertise and state-of-the-art technology to advance your stroke drug development. Please contact us for high-quality biomarker development services.
Reference- Kamtchum-Tatuene, J., & Jickling, G. C. (2019). Blood biomarkers for stroke diagnosis and management. Neuromolecular medicine, 21(4), 344-368.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.Related Services
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket